Prevention of exercise-induced anaphylaxis by ibrutinib.
作者信息
Callisto Alicia, Perkins Griffith Boord, Troelnikov Alexander, Mhatre Shweta, Hissaria Pravin, Smith William
机构信息
Central Adelaide Local Health Network, Adelaide, South Australia, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia; SA Pathology, Adelaide, South Australia, Australia.
出版信息
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2503-2505.e2. doi: 10.1016/j.jaip.2024.05.036. Epub 2024 May 31.
PMID:38823512
Abstract
摘要
相似文献
1
Prevention of exercise-induced anaphylaxis by ibrutinib.
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2503-2505.e2. doi: 10.1016/j.jaip.2024.05.036. Epub 2024 May 31.
2
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: analysis of a large clinical trial safety database.
Haematologica. 2024 Jul 1;109(7):2277-2283. doi: 10.3324/haematol.2023.283846.
3
Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Eur J Haematol. 2018 Sep;101(3):418-420. doi: 10.1111/ejh.13098. Epub 2018 Jun 22.
4
Psoriasis: a new adverse event of ibrutinib.
Ital J Dermatol Venerol. 2024 Apr;159(2):205-207. doi: 10.23736/S2784-8671.23.07735-6. Epub 2024 Jan 29.
5
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Blood Adv. 2024 May 28;8(10):2478-2490. doi: 10.1182/bloodadvances.2023011641.
6
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
Br J Haematol. 2015 Jul;170(1):125-8. doi: 10.1111/bjh.13269. Epub 2014 Dec 18.
7
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Expert Rev Hematol. 2020 Dec;13(12):1303-1310. doi: 10.1080/17474086.2020.1851184. Epub 2020 Dec 9.
8
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
Ann Hematol. 2024 Nov;103(11):4613-4620. doi: 10.1007/s00277-024-05921-7. Epub 2024 Aug 17.
9
Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Am J Ther. 2024;31(4):e453-e455. doi: 10.1097/MJT.0000000000001666. Epub 2024 Feb 2.
10
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica. 2024 Jul 1;109(7):2284-2289. doi: 10.3324/haematol.2023.283861.
引用本文的文献
1
Current and future landscape of Bruton tyrosine kinase inhibitors in allergy.
J Allergy Clin Immunol. 2025 Jun 16. doi: 10.1016/j.jaci.2025.05.030.
Zotero 插件